Irinotecan Hydrochloride 20mg/ml concentrate for solution for infusion (500mg/25ml) Malta - angleščina - Medicines Authority

irinotecan hydrochloride 20mg/ml concentrate for solution for infusion (500mg/25ml)

hospira uk limited - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg - antineoplastic agents

MEDITAB IRINOTECAN irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

meditab irinotecan irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

MEDITAB IRINOTECAN irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

meditab irinotecan irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN-DP irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

irinotecan-dp irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN-GA irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

irinotecan-ga irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN-DP irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

irinotecan-dp irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN-GA irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

irinotecan-ga irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN APOTEX irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection via Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

irinotecan apotex irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection via

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; sodium hydroxide; hydrochloric acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN APOTEX irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

irinotecan apotex irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN INTAS irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

irinotecan intas irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.